Therefore, the deletion of MAVS seems to exert very different actions in mice depending on the time of the genetic intervention and liver status: its deletion is detrimental at early stages in healthy conditions, but it is beneficial when the mice have already developed MASLD. Here, MAVS is linked to metabolic dysfunction-associated steatotic liver disease.